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ABSTRACT
The ongoing pandemic of coronavirus disease 2019 (COVID‑19), caused by severe acute respiratory 
syndrome coronavirus 2 (SARS ‑CoV‑2), represents a major challenge for healthcare. The involvement 
of cardiovascular system in COVID‑19 has been proven and increased healthcare system resources are 
redirected towards handling infected patients, which induces major changes in access to services and 
prioritization in the management of patients with chronic cardiovascular disease unrelated to COVID‑19. 
In this expert opinion, conceived by the task force involving the Working Groups on Valvular Heart Diseases 
and Cardiac Surgery as well as the Association of Cardiovascular Intervention of the Polish Cardiac Society, 
modification of diagnostic pathways, principles of healthcare personnel protection, and treatment 
guidelines regarding triage and prioritization are suggested. Heart Teams responsible for the treatment 
of valvular heart disease should continue their work using telemedicine and digital technology. Diagnostic 
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to COVID‑19.1 Patients with severe VHD must 
remain under telephone surveillance and should 
be encouraged to report progressive symptoms.
If possible, the initial visit of the patient and 
assessment of subjective symptoms should be 
carried out online. This is to protect patients 
from unnecessary contact with healthcare pro‑
fessionals, other patients on the ward, or outpa‑
tients, which may be associated with the risk of 
infection.1,3 When admitting a patient, every cen‑
ter is advised to perform a test for SARS ‑CoV‑2 
(preferably using the polymerase chain reaction 
[PCR]‑based assay) and carry out triage selection 
to assess the patient’s risk status. During admis‑
sion to a cardiology clinic or hospitalization, it 
is crucial to reduce the risk of transmitting in‑
fection to healthy patients by the medical per‑
sonnel and to protect medical teams (whose in‑
fection status should be verified with diagnos‑
tic tests) against infection or unnecessary con‑
tact with people with COVID‑19 or those who 
are at risk of developing the disease. In patients 
with suspected COVID‑19 (people in quarantine 
awaiting the test result and those with a history 
indicative of possible infection), invasive proce‑
dures should be deferred as far as possible, until 
infection is either confirmed or excluded (usually 
the day after testing). In directly life ‑threatening 
situations (eg, acute valve regurgitation or pros‑
thetic valve dysfunction), persons with an un‑
clear epidemiological status should undergo pro‑
cedures without delay. During the procedures, 
protocols regarding the management of people 
with confirmed infection should be followed.4 
Urgent procedures should be performed accord‑
ing to the protocols used so far.
It is essential to perform diagnostic tests for 
SARS ‑CoV‑2 in patients with VHD just before 
any nonurgent admission to the hospital. As 
the epidemic may last in Poland for the follow‑
ing month, it is advisable to gradually expand 
the scope of diagnostic procedures and treat‑
ment using the appropriate personal protective 
equipment (PPE).
Organization of Heart Teams during 
the  coronavirus  disease  2019  pandemic 
A Heart Team is a group of experienced spe‑
cialists, including cardiologists (clinical 
Introduction Severe acute respiratory syn‑
drome coronavirus 2 (SARS ‑CoV‑2) infection has 
presently become a rapidly spreading pandem‑
ic. The virus penetrates into the lungs, the heart, 
the  kidneys, or gastrointestinal cells using 
the angiotensin ‑converting enzyme 2 (ACE2) 
and receptor ‑mediated endocytosis. This may 
explain the wide spectrum of clinical symptoms. 
In addition, recent reports have emphasized 
the high risk of thromboembolic complications, 
which was particularly notable in nonsurvivors.1
The treatment of coronavirus disease 2019 
(COVID‑19) is based on the use of various drugs 
(antivirals, antimalarials, antibiotics, and drugs 
affecting specific inflammatory pathways). In 
the case of respiratory or multiorgan failure, 
mechanical support may be necessary. Howev‑
er, several therapeutic strategies have proved to 
be partially ineffective or unsuccessful. Actual‑
ly, there are no recommendations for using any 
antiviral drug or drug combination in Poland, 
which is why adaptation of adjuvant therapies 
is justified to achieve better outcomes.
About 81% of patients with COVID‑19 have 
moderate symptoms and recover quickly, but 
14% of patients develop severe respiratory fail‑
ure requiring mechanical ventilation. The severe 
course of the disease is particularly frequently 
observed in patients over 65 years of age. Pul‑
monary or cardiac disease, diabetes, hyperten‑
sion, and obesity are the risk factors for unfa‑
vorable outcomes.2 Obviously, patients with val‑
vular heart disease (VHD) are also included in 
this risk group.
Patient care before, during, and after hospi‑
talization during the coronavirus disease 2019 
pandemic The primary purpose in the man‑
agement of patients with VHD during the COV‑
ID‑19 epidemic is to select those who require ur‑
gent intervention and those who may be moni‑
tored and treated pharmacologically. In patients 
who may be qualified for surveillance and in 
whom intervention may be safely postponed, 
such procedures should be preferred. Further‑
more, pharmacotherapy and watchful waiting 
need to be implemented, with an individually ad‑
justed frequency of follow ‑up visits, particularly 
in those at high risk of unfavorable outcome due 
tests must be simplified or deferred to minimize the number of potentially dangerous aerosol ‑generating 
procedures, such as transesophageal echocardiography or exercise imaging. The treatment of aortic 
stenosis and mitral regurgitation has to be offered particularly due to urgent indications and in patients 
with advanced disease and poor prognosis. Expert risk stratification is essential for triage and setting 
the priority lists. In each case, an appropriate level of personal protection must be ensured for the healthcare 
personnel to prevent spreading infection and preserve specialized manpower, who will supply the continuing 
need for handling serious chronic cardiovascular disease. Importantly, as soon as the local epidemic 
situation improves, efforts must be made to restore standard opportunities for elective treatment of 
valvular heart disease and occluder ‑based therapies according to existing guidelines, thus rebuilding 
the state ‑of ‑the ‑art cardiovascular services.
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The shortened and modified protocol of ex‑
amination, ensuring personal protection, is of 
key importance. Staff members with particular 
risk factors, such as advanced age of 65 years or 
more, chronic conditions, pregnancy, or immu‑
nosuppression, may be advised not to come in 
contact with patients with COVID‑19.8
Echocardiographic examinations should be 
performed at the patient’s bedside using por‑
table devices. The increasing role of point ‑of‑
‑care ultrasound (POCUS) focused on lung ul‑
trasound or cardiac problem ‑oriented exami‑
nation (focused cardiac ultrasound [FoCUS]) is 
reported. When severe VHD is suspected, and 
clinical data support the potential necessity for 
surgical or interventional treatment, it is justi‑
fied to perform full TTE examination to confirm 
the significance of VHD.
Computed tomography, nuclear examina‑
tion, and nuclear magnetic resonance imag‑
ing Computed tomography is currently not rec‑
ommended as a screening tool for COVID‑19. In 
patients with VHD, indications for CT include: 
diagnostic workup before urgent transcatheter 
aortic valve implantation (TAVI), transcathe‑
ter mitral valve implantation, and due to pros‑
thetic valve dysfunction or thoracic aortic aneu‑
rysm. Other clinically relevant indications dur‑
ing the COVID‑19 pandemic include: diagnosis of 
coronary artery disease, particularly before val‑
vular surgery, suspected pulmonary embolism, 
and exclusion of thrombi in the heart cavities, 
particularly before cardioversion.9
Computed tomography, and, rarely during 
the pandemic, single ‑photon emission comput‑
ed tomography with labeled leukocytes or posi‑
tron emission tomography are recommended in 
patients in whom infective endocarditis is sus‑
pected, particularly in those with valvular pros‑
theses or implantable devices.9,10
The role of NMR imaging in cardiac diagnos‑
tic workup during the pandemic is not well es‑
tablished; however, it may be crucial when myo‑
carditis is suspected.11
Imaging should be limited only to those sit‑
uations when it is clinically relevant and may 
significantly influence patients’ treatment, to 
evaluate the severity of VHD or left ventricu‑
lar dysfunction, and to prepare for urgent sur‑
gical or interventional treatment (eg, coronary 
artery multislice computed tomography or com‑
puted tomography angiography before TAVI).8,9
Intraoperative echocardiography during 
the  coronavirus  disease  2019  pandemic 
Transesophageal echocardiography in nonintu‑
bated patients is considered an examination of 
high risk of COVID‑19 spread due to possible di‑
rect droplet transmission and / or transmission 
during positioning of the probe. After intubation, 
the risk of virus transmission decreases, but it 
cardiologists, echocardiographers, and inva‑
sive cardiologists), cardiac surgeons, anesthesi‑
ologists, and, optionally, vascular surgeons and 
other specialists.5 Heart Teams are dedicated to 
consult patients referred for interventional pro‑
cedures including cardiac surgery.6
Recently, various organization models for 
Heart Teams were established; however, dur‑
ing a pandemic, the most crucial task is to main‑
tain the continuity of work. Currently, the es‑
sential clinical and imaging data are trans‑
ferred electronically (using telemedicine or oth‑
er means of virtual communication) to avoid di‑
rect contact between physicians. Phone calls are 
used when a face ‑to ‑face meeting is impossible. 
The Heart Team’s recommendation is also sent 
back electronically.
In the era of a pandemic, the key issue is to en‑
sure the safety of the medical team performing 
consultations. Therefore, Heart Team members 
should use standard personal protection equip‑
ment and keep the distance. Online consulta‑
tions based on videoconference application and 
transmission of imaging data are recommended 
if available. Unfortunately, such a solution is ac‑
tually limited. At the current stage, the consul‑
tation model described above is advised.
Noninvasive imaging during the coronavi‑
rus disease 2019 pandemic When noninva‑
sive imaging is required in patients with VHD, 
the time and mode of examination are deter‑
mined by patients’ epidemiological and clini‑
cal status. In patients with suspected or con‑
firmed infection, imaging should not be rou‑
tinely performed. Elective, nonurgent examina‑
tion should be performed after completed treat‑
ment for COVID‑19. Imaging should be limited 
only to those situations when it is clinically rel‑
evant and may significantly influence patients’ 
treatment.7,8
Of note, the highest risk of virus transmis‑
sion occurs during transesophageal echocardiog‑
raphy (TEE) and is higher than during trans‑
thoracic echocardiography (TTE) or other im‑
aging examinations, such as those performed 
with the use of computed tomography, nuclear 
magnetic resonance (NMR) imaging, scintigra‑
phy, or positron emission tomography. Exercise 
imaging in VHD is a potentially risky, aerosol‑
‑generating procedure and should be deferred 
during the pandemic.
Echocardiography  and  ultrasonography 
Transthoracic echocardiography and TEE pose 
a risk of infection transmission. Transesophageal 
echocardiography should be performed only due 
to lifesaving indications, provided that other im‑
aging modalities are inappropriate or inconclu‑
sive in a particular clinical problem. Transthorac‑
ic echocardiography requires direct contact with 
the patient and poses a risk of infection spread.
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syndrome. Besides, cooperation with the Extra‑
corporeal Life Support Organization can be use‑
ful when treating patients with COVID‑19. Ex‑
cept for urgent and / or lifesaving indications, 
patients with confirmed COVID‑19 and VHD 
should be operated after the treatment of CO‑
VID‑19 is completed. During the pandemic, car‑
diac surgeons should sometimes choose more 
conservative rather than invasive treatment if 
the situation requires such approach.
Specific recommendations regarding operat‑
ing rooms The first step of the surgical proce‑
dure should comprise decision making and an‑
swering the question as to whether the proce‑
dure is absolutely necessary at present and what 
will happen if it is not performed. An “airway 
team” should include an anesthesiologist and 
a member of the operating room staff. If the pa‑
tient is anesthetically challenging, consider in‑
volving an additional anesthesiologist. The scrub 
team should remove all unnecessary equipment 
from the operating room. It is recommended 
to plan the organization of the operating room 
staff to ensure that there is a “clean” runner out‑
side the operating area (who will be in the an‑
esthetic room, wearing an FFP3 mask, goggles, 
a plastic apron, and gloves) and the number of 
staff members present in the operating room 
is reduced to a minimum. The operating room 
staff, unlike the airway team, should wait out‑
side during patient intubation (even though they 
use full PPE, since unnecessary exposure needs 
to be avoided). No staff member can be asked to 
reduce their level of personal protection against 
their wishes. Transfer to the operating room 
should be organized as follows: the transport‑
ing team should wear simple PPE. The patient 
should be transported in a dedicated tent and 
wear an FFP3 mask if COVID‑19 is suspected or 
confirmed. If the patient receives oxygen sup‑
port, a mask or another simple cover should be 
loosely placed over the oxygen mask. The most 
direct route to the operating room should be tak‑
en, bypassing the anesthetic preparation room. 
If possible, the patient’s bed should be left in 
the operating room during the procedure. Notes 
and other medical documentation should be 
left with the patient. Rapid transit pathways, if 
available, should be used when transporting pa‑
tients with confirmed or possible COVID‑19. In 
the operating room, the anesthesiologists’ pro‑
tocol should be strictly followed during the intu‑
bation process: full PPE, with the second pair of 
nonsterile gloves and a plastic apron on the top 
of the gown, need to be worn during all intuba‑
tions and extubations regardless of the patient’s 
COVID‑19 status (even if the disease is not sus‑
pected). The airway team dons in the scrub area 
before the patient arrives. The patient should 
be anesthetized and intubated in the operat‑
ing room. Intubation needs to be performed by 
is still possible through patients’ secretions car‑
ried on the TEE operator’s gloves.
Patients with suspected or confirmed 
COVID‑19 should be operated on in separate op‑
erating rooms. Those with confirmed COVID‑19 
may require TEE in many clinical situations, in‑
cluding cardiac surgery. This examination is es‑
sential in the following valvular diseases: left‑
‑sided endocarditis with a severe valvular de‑
fect or perivalvular involvement; symptomat‑
ic severe mitral valve insufficiency; prosthetic 
valve dysfunction; Stanford type A aortic dis‑
section associated with aortic valve insufficien‑
cy, aortic root dissection, or pericardial effusion; 
or in another specific condition.
Transesophageal echocardiography should be 
performed by an experienced echocardiographer. 
Obtained imaging data should be recorded and 
not only focused on the main pathology but also 
they must be extensive enough to detect other 
significant, unexpected abnormal findings.12,13 
Personnel protection and prevention against 
virus transmission should be a priority during 
the COVID‑19 pandemic.
The levels and categories of PPE and the way 
of disinfecting echocardiography machines and 
TEE probes are covered in detail in the main ex‑
pert opinion of the Working Group on Echocar‑
diography of the Polish Cardiac Society.8
Surgical treatment of valvular heart dis‑
ease during the coronavirus disease 2019 
pandemic If the patient has tested positive for 
SARS‑CoV‑2 and an operation is needed, the ex‑
posure time and the number of medical staff  
members involved should be reduced in the op‑
erating room. In addition, particularly during 
endoscopic procedures, it is crucial to reduce 
the time of exposure to patients’ aerosol, as they 
may be unrecognized, asymptomatic carriers of 
COVID‑19.8 Social distancing is another step 
to minimize the risk of transmission. Redirec‑
tion of hospital equipment and PPE to emergen‑
cy rooms prepared for patients with COVID‑19 
is recommended. Reduced utilization will con‑
serve it for future critical incidents. This recom‑
mendation is also valid for blood unit conserva‑
tion in the case of lower availability of donors. 
The number of blood units reserved for elective 
procedures should be reduced. The number of 
medical staff members must be reduced due to 
redeployment or COVID‑19 developed among 
them. Each case should be individually discussed 
with regard to operation risk, alternative ther‑
apies such as medical treatment, percutaneous 
intervention, or readmission to another hospi‑
tal offering higher availability of therapies for 
COVID‑19. The experience of cardiac surgeons, 
involved in advanced cardiac disease treatment, 
can be utilized in implementing extracorpore‑
al membrane oxygenation (ECMO), which is 
successfully used in acute respiratory distress 
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symptomatic patients with severe AS.14 Lack of 
intervention is associated with poor prognosis 
and high 1‑year mortality.15
According to the  ESC guidelines, due to 
the limited possibility of intervention during 
the pandemic, patients with severe AS require 
risk restratification.7 It seems necessary to se‑
lect vulnerable patients who need intervention 
first. Patients who are less symptomatic and 
have invasive treatment delayed will be included 
in the “waiting group.” This group requires par‑
ticularly close outpatient monitoring. It seems 
that regular telephone contact will be relevant 
for the retriage of this patient group.
The group at higher risk should include pa‑
tients with severe symptomatic AS and: de‑
creased left ventricular ejection fraction (LVEF), 
symptomatic heart failure (HF) classified as 
the New York Heart Association (NYHA) class 
III to IV, syncope secondary to AS, and a high or 
very high transvalvular gradient.16 This group 
requires an urgent intervention or balloon aor‑
tic valvuloplasty may be considered in this 
population.
Patients with mild symptoms of severe AS 
(HF with the NYHA class I to II) and asymp‑
tomatic patients should be qualified for surgery 
at a later date,17 which will depend on the capac‑
ity of the center.
It seems that in the current, unusual epide‑
miological situation, the Heart Team plays a key 
role in the proper stratification of patients with 
AS. It is the Heart Team who should decide which 
patients with AS require intervention or sur‑
gery first, and which types of interventions are 
recommended (indications for TAVI may be ex‑
tended to intermediate and selected low ‑risk pa‑
tients). The regular assessment of patients on 
the “AVR waiting list” is crucial.18
Patients with AS should be treated individu‑
ally, so that they do not lose the chance of sur‑
gery or intervention during the optimal period. 
Hospitals should consider both patients’ medi‑
cal needs and the logistic capacity to meet these 
needs in a timely manner.13
Transcatheter aortic valve implantation Cur-
rent situation and the proposed strategy for trans-
catheter aortic valve implantation in the era of 
the coronavirus disease 2019 pandemic  Trans‑
catheter aortic valve implantation is the proce‑
dure of choice for the treatment of symptom‑
atic AS in patients excluded from convention‑
al surgical treatment (surgical aortic valve re‑
placement [SAVR]) and the equivalent therapy 
for SAVR patients at high and moderate oper‑
ational risk.5,19 The COVID‑19 pandemic, espe‑
cially in its early phase, was associated with lo‑
gistic changes in the operation of hospital facil‑
ities and the reduction or centralization of hu‑
man resources and equipment directed at se‑
lection (non ‑COVID‑19 hospitals) and care 
the most experienced anesthesiologist. Only key 
staff members should be present for intubation 
(the chief anesthetist, an operating department 
practitioner). Consider turning the tempera‑
ture down in the operating room, as there have 
been numerous reports on overheating while 
wearing full PPE.
The operation It is recommended for all staff 
members to wear full PPE. Discretion can be 
used to opt for simpler PPE, as discussed above, 
particularly in COVID‑19‑negative cases; howev‑
er FFP2 or FF3 masks are necessary. Those scrub‑
bing for the procedure should enter through 
the scrub area with FFP3 masks and eye pro‑
tection in place, and then scrub as usual. Oth‑
er staff members need to don outside and en‑
ter the room in full PPE. The scrub and surgi‑
cal teams may enter the room once the airway 
is secured. All should wait for the anesthesiol‑
ogist’s instructions.
All staff, apart from the airway team, should 
leave the operating room before extubation. 
No other staff members can enter the operat‑
ing room for 20 min, unless they wear full PPE. 
The anesthetic team should stay with the pa‑
tient in their full PPE until the patient is awake, 
normally breathing, and any risk of reintuba‑
tion has passed. The patient should be calm, re‑
ceiving reasonable analgesic treatment, and not 
nauseated. If COVID‑19 is not suspected, the pa‑
tient can be moved to the recovery room. Oth‑
erwise, if COVID‑19 is confirmed or possible, 
20 min following the extubation, the anesthet‑
ic team can transition the patient’s care to a re‑
covery nurse in the operating room, wearing full 
PPE, and transfer the patient back to an appro‑
priate ward. Return to the ward or general in‑
tensive care unit (ICU) should follow a similar 
pattern as in the case of transporting the pa‑
tient to the operating room: the patient should 
be kept intubated. Maintain full PPE, as the pa‑
tient will be switched to transfer ventilator tub‑
ing and, then, a general ICU ventilator, which 
poses the risk of inhaling aerosols by the medi‑
cal team. Clamp the endotracheal tube prior to 
planned circuit disconnection and ensure that 
the heat and moisture exchanger is always pres‑
ent in the circuit.
Doffing PPE should take place where the pa‑
tient is left, outside the patient’s room or area. 
For transporting patients with confirmed or pos‑
sible COVID‑19, the rapid transit pathway should 
be used where the security staff is responsible 
for clearing corridors, calling lifts, etc.
Aortic stenosis: indications for interven‑
tion and monitoring during the coronavi‑
rus disease 2019 pandemic Aortic steno‑
sis (AS) is the most common primary valvular 
heart disease. Aortic valve replacement (AVR) or 
transcatheter procedures are recommended for 
E X P E R T  O P I N I O N  A N D  P O S I T I O N  P A P E R  Cardiac disease during the COVID-19 pandemic 503
where diagnostic and therapeutic procedures 
are performed in patients with an undeter‑
mined status of SARS ‑CoV‑2 infection. Due to 
the desirable minimization of the ICU load, pa‑
tient safety, the lowest possible involvement of 
human resources and equipment, and the ex‑
pected shortening of hospital stay, conducting 
TAVI through femoral access under conscious 
sedation and / or local anesthesia is feasible and 
seems to be the optimal solution. Patients with 
confirmed high ‑risk AS (TABLE 1) and the negative 
COVID‑19 status require standard, precise diag‑
nostic workup prior to TAVI (coronary angiogra‑
phy, computed tomography angiography). Both 
diagnostic and procedure ‑related hospital stay 
must be shortened. The above considerations 
also apply to patients who, due to age, general 
condition, or comorbidities with poor progno‑
sis (eg, cancer), are scheduled to have balloon 
aortic valvuloplasty performed as a bridging or 
destinaton therapy.
Cardiac surgery for aortic stenosis Postpon‑
ing or rescheduling the procedures is the princi‑
pal recommendation in patients on the waiting 
list for cardiac surgery, if the likelihood of signif‑
icantly impacting the further course of the dis‑
ease is low.7 The reasons for that are multifacto‑
rial and involve protecting the cardiac patient by 
avoiding exposure to those with either suspected 
or confirmed COVID‑19 in increasingly populat‑
ed hospitals, which reduces the risk of infection. 
Additionally, protecting the institution and re‑
sources will result in preserving valuable means 
including ICU beds, ventilators, ECMOs, phar‑
maceuticals, and PPE. Lastly, it protects the car‑
diac surgery team consisting of highly special‑
ized and dedicated individuals (scrub nurses, 
cardiac anesthesiologists, perfusionists, and 
surgeons), thus reducing their exposure to CO‑
VID‑19, which may affect healthcare profession‑
als in the next instances. It is recommended to 
organize telemedicine ‑based healthcare system, 
(COVID‑19‑specialized hospitals) of patients 
with COVID‑19; it also significantly reduced 
the number of procedures performed in patients 
with symptomatic AS, both SAVR and TAVI.7,13 
Of note, considering the natural course of AS, 
a very high 1‑year mortality rate is reported in 
symptomatic patients treated only conservative‑
ly, reaching even 50%. In the light of these data, 
a quick yet gradual (depending on the develop‑
ment of the epidemiological situation in Poland) 
return to interventional treatment of symptom‑
atic patients with AS should be attempted. It is 
advisable to first qualify patients with the high‑
est risk of AS. High ‑risk clinical and echocardio‑
graphic features that should prompt accelerated 
or semi ‑urgent (up to 1 to 2 months in the time 
horizon) and, in selected cases, even in emergent 
and urgent referral (cardiogenic shock, severe 
NYHA class IV HF) are listed in TABLE 1. The deci‑
sion on the date of procedure for hemodynam‑
ically stable patients without deterioration of 
echocardiographic features can be postponed, 
but, given the poor prognosis of patients treated 
only conservatively, this group should be close‑
ly monitored with regular follow‑ups, prefera‑
bly using telemedicine.
Logistic aspects of preparing patients to 
aortic interventions and the optimal trans‑
catheter aortic valve implantation tech‑
nique during the coronavirus disease 2019 
pandemic The risk of spreading infection to 
the medical staff and the patient should be max‑
imally reduced by the obligatory determination 
of the initial COVID‑19 status using the PCR 
swab test, preferably a test enabling clinicians 
to obtain results after several hours. While wait‑
ing for test results, the patient should remain 
in the separated buffer zone of the ward or hos‑
pital and be treated as potentially infected. Af‑
ter confirming the negative result, it is recom‑
mended to perform TAVI in a hybrid room or he‑
modynamic laboratory separated from the sites 
TABLE 1 High ‑risk factors for transcatheter aortic valve implantation recommended within up to 1 to 2 months
Clinical • Cardiogenic shocka
• Decompensated HF with NYHA class III or IVa
• Recurrent syncopal or presyncopal episodes
• Recurrent chest pain
• Aortic bioprosthetic valve dysfunction with severe regurgitation
Echocardiographic • Vmax >5 m/s
• PGmax >100 mm Hg
• Significant reduction of LVEF in a short time
a Emergent (balloon aortic valvuloplasty to be considered as a bridging procedure before transcatheter aortic valve implantation or 
surgical aortic valve replacement), particularly in patients with an uncertain coronavirus disease 2019 status and without computed 
tomography angiography performed—procedures with the use of full personal protective equipment by the medical staff as well as 
the proper disinfection of the room after they have been performed, as in patients diagnosed with coronavirus disease 2019
Abbreviations: COVID-19, coronavirus disease 2019; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PG, 
pressure gradient; V, velocity
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is necessary to reorganize the admission system 
and set new priorities. The slow deceleration of 
the COVID‑19 pandemic, currently observed in 
some countries, forces clinicians to take further 
actions aimed at re‑initialization of standard con‑
sultations and treatment in patients with VHD 
who stay at home and benefit exclusively from 
medical consultations using a telemedicine sys‑
tem.13,17 Patients with MR can now be classified 
into 3 different categories (tiers). The group re‑
quiring the most urgent procedures (tier 1) in‑
cludes patients with acute MR and decompensat‑
ed HF with NYHA class IV requiring intra ‑aortic 
balloon pump support and inotropic drugs. Low‑
‑priority procedures (tier 2) should be assigned 
to those with chronic MR, episodes of cardiac de‑
compensation, lack of response to pharmacother‑
apy and cardiac resynchronization therapy, and 
a decrease in LVEF. The third category (tier 3) in‑
cludes patients in whom surgical treatment may 
be postponed. The strategies of performing inter‑
ventions in patients with MR, based on the ESC 
recommendations7 and the American experience 
of Chung et al,17 are presented in TABLE 2.
Percutaneous procedures limiting mitral re‑
gurgitation with the use of the edge ‑to ‑edge 
technique The  edge ‑to ‑edge procedures 
proved to be safe thanks to the support offered 
by an anesthesiologist, continuous periproce‑
dural TEE monitoring, and 24‑hour postoper‑
ative surveillance in the ICU. However, during 
the pandemic, this procedure could be associat‑
ed with increased exposure of the medical staff 
to coronavirus transmission (during intubation 
and TEE monitoring) and exhaustion of the al‑
ready depleted resources, that is, the medical 
personnel and ICU beds. It is of importance to 
set an appropriate priority when deciding wheth‑
er to perform an intervention in an already hos‑
pitalized patient or to admit a patient for elec‑
tive treatment.
particularly focused on monitoring the patients 
awaiting postponed procedures. Hospital bed 
capacity, particularly intensive care backup for 
current epidemic needs, is another reason for 
cancelling or postponing the surgeries.
In patients who need urgent intervention, sur‑
gery should be conducted to avoid patient’s harm. 
This group of patients who may require urgent 
surgical procedures includes those with severe 
symptomatic AS and HF with NYHA class III 
to IV and syncope secondary to AS. Preopera‑
tive preparation of the patient is similar as for 
TAVI, with obligatory testing for SARS ‑CoV‑2 
within 24 to 48 hours before surgery. Patients 
appropriately qualified for AVR can be success‑
fully treated with hospitalization below 7 days, 
as indicated. Current guidelines should be fol‑
lowed regarding the choice of treatment in pa‑
tients with severe AS who are scheduled for ur‑
gent intervention.
Management of patients with mitral regur‑
gitation during the coronavirus disease 2019 
pandemic So far, neither any direct effect of 
COVID‑19 on the clinical course of primary (or‑
ganic) and secondary (functional) mitral regurgi‑
tation (MR) nor any impact on the valvular func‑
tion have been demonstrated. However, as in 
the management of other cardiovascular diseases, 
the COVID‑19 pandemic imposed a series of pro‑
cedural and logistic changes in terms of treatment 
strategies and hospital as well as ambulatory care.
The vast majority of patients with asymptom‑
atic severe MR do not require urgent interven‑
tions and treatment may be postponed. Such pa‑
tients may stay at home and can be monitored 
using a telemedicine system.
During the COVID‑19 pandemic, general clin‑
ical indications for surgical treatment of organ‑
ic or functional and acute or chronic MR remain 
unchanged, while the priority for both surgical 
and percutaneous interventions has changed. It 
TABLE 2 Strategy for mitral interventions during the coronavirus disease 2019 pandemic according to the 
European Society of Cardiology7 and Chung et al17
Tier 1 Tier 2 Tier3
Emergency  
(do not postpone)
Urgent  
(perform within days)
Lower priority  
(perform in <3 months)
Elective  
(postpone for >3 months)
Surgical replacement or repair:
Acute postinfarction MR, acute 
infectious (IE) regurgitation of 
a native valve or mitral 
prosthesis, complicated by 
cardiogenic shock
Decompensated MR requiring 
IABP support, inotropes
MitraClip procedure: 
Acute postinfarction MR 
without shock in 
inoperable patients
Decompensated MR with 
NYHA class IV
Surgical replacement:
Acute postinfarction and 
postinfective (IE) MR, 
without shock
MitraClip procedure or 
surgical treatment:
Functional MR in 
the course of 
decompensated heart 
failure, despite optimal 
pharmacotherapy / CRT, 
with NYHA class III, with 
EF decrease
MitraClip procedure or 
surgical treatment: 
Functional MR with 
a stable course of heart 
failure, without 
escalating diuretic 
treatment, with NYHA 
class I to II
Abbreviations: CRT, cardiac resynchronization therapy; EF, ejection fraction; IABP, intra ‑aortic balloon pump; IE, infective endocarditis; 
MR, mitral regurgitation; others, see TABLE 1
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of SARS ‑CoV‑2 infection in patients and the med‑
ical staff, as well as the disrupted workflow in 
heart valve centers. The key issues are limited 
blood donation and supply, which can jeopardize 
the access to blood products if complications oc‑
cur, need for urgent cardiac surgery, and expo‑
sure of the medical staff to aerosols during in‑
tubation and TEE examination. Also, the short‑
age of the experienced anesthesiology staff may 
be the limiting factor.7,17 Given the fact that pa‑
tients with MR are usually at high risk of death if 
infected with SARS ‑CoV‑2 (due to age >65 years, 
HF, coronary heart disease, hypertension, and 
chronic obstructive pulmonary disease), prepro‑
cedural testing with the PCR test, separation 
from other patients, and fast discharge are rea‑
sonable steps to be taken.
The decision to perform an intervention in 
an already hospitalized patient or to admit a pa‑
tient for treatment during the COVID‑19 pan‑
demic should be preceded by evaluating the se‑
verity of clinical symptoms of MR, valve mor‑
phology, patient prognosis, and should be also 
based on a reliable and reasonable assessment of 
hospital resources (FIGURE 1). Patients with “simple” 
valvular anatomy, symptoms, and good long‑
‑term prognosis should be prioritized for per‑
cutaneous treatment if hospital resources are 
not limited.
Other transcatheter mitral valve interven‑
tions In addition to the procedures reducing 
MR, transcatheter mitral valve interventions in‑
clude percutaneous mitral commissurotomy in 
patients with severe mitral stenosis (MS), as well 
as the closure of paravalvular leaks with occlud‑
ers. Percutaneous mitral commissurotomy should 
be performed in specialized centers by experi‑
enced operators, only in patients with significant 
rheumatic MS if the risk ‑to ‑benefit ratio is ac‑
ceptable. The following groups of patients should 
be considered: 1) pregnant women (>20 weeks of 
pregnancy) with HF related to MS (NYHA class 
III to IV) or pulmonary hypertension (systolic 
pulmonary artery pressure >50 mm Hg) despite 
optimized medical therapy; 2) patients with HF 
(NYHA class III to IV) with comorbidities exac‑
erbating the disease, which cannot be adequate‑
ly controlled (eg, atrial fibrillation and poor rate 
control).5 Transcatheter closure of paravalvular 
leaks should be considered in those without ac‑
tive infectious endocarditis who present with HF 
(NYHA class III to IV) or severe hemolytic ane‑
mia requiring transfusions.5
Surgical management of mitral regurgita‑
tion in the era of the coronavirus disease 
2019 pandemic The majority of patients with 
MR are stable and can have surgical interven‑
tions deferred. Decisions on whether to perform 
cardiac surgery or not will be easier in the low‑ 
and medium ‑escalation phase of the COVID‑19 
The highest priority for performing edge ‑to‑
‑edge procedures during the COVID‑19 pandem‑
ic has been currently granted to the following 
groups of patients: 1) patients with severe MR 
and HF (NYHA class III to IV) despite optimal 
medical therapy and CRT when indicated, espe‑
cially in the case of recurring appearance of HF 
decompensations requiring hospitalization with‑
in the preceding 30 days and / or NYHA class III 
to IV symptoms refractory to pharmacothera‑
py or requiring inotropes or mechanical cardi‑
ac support; refractory HF precluding discharge 
from the hospital; 2) patients with acute MR as 
a mechanical complication of myocardial infarc‑
tion or related to the rupture of mitral chordae 
tendineae who fulfill the anatomical feasibility 
criteria and are deemed inoperable, except for 
those with infectious endocarditis.13,17
Of note, in patients with secondary MR who 
fulfill the COAPT (Cardiovascular Outcomes As‑
sessment of the Mitraclip Percutaneous Thera‑
py) inclusion criteria, the MitraClip procedure 
not only reduces the number of hospitaliza‑
tions due to HF but also decreases mortality, 
so it should not be postponed longer than ab‑
solutely necessary.17,20
Similarly to other transcatheter interven‑
tions, patients’ qualification should be based on 
the analysis of the risk ‑benefit profile. The fac‑
tors to be considered are the potential mortality 
and morbidity benefit of the procedure, the risk 
FIGURE 1 Decision criteria for prioritizing transcatheter treatment of mitral regurgitation, 
including clinical symptoms, mitral valve anatomy, prognosis and availability of medical staff, 
intensive care unit beds, and personal protective equipment. Based on Shah et al13
Mitral valve anatomy
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In the time of significant and high incidence 
of COVID‑19 in the community, elective proce‑
dures may (and, in infected patients, should) be 
deferred. In extremely rare urgent indications 
for the procedure in a patient infected with 
SARS ‑CoV‑2 (eg, due to a mechanical complica‑
tion of myocardial infarction), decisions must be 
made on a case ‑by ‑case basis. The use of a venti‑
lator during surgery may reduce the risk of virus 
transmission.
However, in an epidemiological scenario with 
a moderate incidence of COVID‑19, it is advis‑
able to very gradually restore access to elective 
and prophylactic procedures in accordance with 
current guidelines, while maintaining the above 
mentioned safety measures and pretreatment 
testing for SARS ‑CoV‑2.7 The duration of hos‑
pital stay and extent of in ‑hospital procedures 
performed in addition to the essential treatment 
should be minimized.
Anticoagulant management in patients with 
valvular heart disease Limited access to 
healthcare and patients’ anxiety, which leads 
to avoiding office visits and laboratory testing, 
may adversely influence the international nor‑
malized ratio (INR) control in patients with me‑
chanical valves who take vitamin K antagonists 
(VKAs). This can result in taking subtherapeu‑
tic VKA doses and an increased risk of throm‑
boembolic events or bleeding related to over‑
dose. Specifically, the thrombotic risk may be 
increased in patients with COVID‑19.
We recommend to continue regular INR 
evaluation in patients with mechanical valves. 
Patients with mechanical prosthetic valves 
should continue anticoagulation with VKAs, 
yet non–vitamin K antagonist oral anticoagu‑
lants are contraindicated. Of note, in patients 
with stable VKA anticoagulation, the frequen‑
cy of INR monitoring can be reduced to 10 to 
12 weeks between INR checks. Organization of 
outpatient clinics and INR evaluation should 
be modified in order to limit close personal con‑
tacts. Importantly, if it is possible for the pa‑
tient to self ‑test the INR using a CoaguChek de‑
vice, this should be recommended. In such cas‑
es, the physician should adjust the VKA dose 
by phone. Moreover, when INR monitoring is 
not possible, low ‑molecular ‑weight heparin 
at a full therapeutic dose could be considered 
for a short time if the patient can be taught to 
self ‑inject the drug or a caregiver can admin‑
ister the injection.7,22
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pandemic when the ICU beds will be still avail‑
able. Continued escalation will make decisions 
to operate more difficult. In a progressively esca‑
lating situation, routine elective cardiac surgery 
should not be performed.7 Priority should be given 
to treating patients with: acute MR complicating 
acute myocardial infarction; infective endocar‑
ditis; MR due to acute degenerative chordal rup‑
ture; severe, symptomatic primary or secondary 
MR that is not responsive to guideline ‑directed 
medical and CRT treatment and requires hospital 
admission; and MR with low ejection fraction.13,17
Patients with chronic primary MR (a flail leaflet 
and Barlow disease) are usually stable and proce‑
dures may be postponed in this population. Surgi‑
cal repair in such patients should be deferred un‑
til the end of the COVID‑19 pandemic. Close out‑
patient monitoring using telemedicine should be 
continued in all patients with severe MR. After 
decompensation requiring hospitalization, proper 
surgical intervention should be undertaken (TABLE 2).
Patients with suspected or confirmed 
COVID‑19 should undergo procedures in dedi‑
cated operating rooms only if an urgent or emer‑
gent indication exists, as potential myocardial 
and pulmonary complications due to COVID‑19 
may occur. The choice of intervention (surgical 
or transcatheter) should be guided by the local 
Heart Team.21
Transvascular implantation of occluders in 
patients with cardiac disease Percutaneous 
implantation of occluders is a standard proce‑
dure used to treat hemodynamically significant 
congenital heart disease (shunt lesions in atri‑
al and ventricular septal defects, patent ductus 
arteriosus) and to reduce the risk of cardiogenic 
embolism (closure of the patent foramen ovale 
or the left atrial appendage). These procedures 
are almost invariably elective. Scenarios which 
require urgent (within a few days) implantation 
of an occluder are very rare and include, for ex‑
ample, implantation of an occluder into the ven‑
tricular septal rupture (usually being a compli‑
cation of myocardial infarction), severe peri‑
valvular leak, or atrial septal defect associated 
with the high risk of paradoxical embolism, eg, 
in acute deep vein thrombosis.
Since occluder implantation is performed in 
the cardiac catheterization laboratory, usually 
under TEE guidance, it is considered a high ‑risk 
procedure due to possible droplet transmission 
and generation of aerosols, which requires pro‑
longed contact between the patient and the med‑
ical staff. Therefore, it belongs to the category 
of treatments which can be postponed during 
the coronavirus pandemic. In clinically justified 
situations, exclusion of coronavirus infection 
must precede the procedure which is to be car‑
ried out wearing the adequate PPE (an isolation 
gown, eye protection, and a respirator, at least 
of class FFP2 / N95).
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